HCC

Survival Improved With HAIC Over Standard TACE in Unresectable HCC

September 20, 2020

A significant improvement in overall survival was observed with the addition of hepatic arterial infusion chemotherapy to oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Priming With Tremelimumab Leads to Greater Efficacy for Durvalumab Treatment in Advanced HCC

September 16, 2020

“In sum, these data show that T300+D regimen provides the best benefit-to-risk profile across arms,” Robin Kate Kelley, MD, said of Study 22 in hepatocellular carcinoma.

Improving Upon Immunotherapy Advances in HCC

September 14, 2020

Bruno Sangro, MD, PhD, discusses the key takeaways from recent data in the treatment landscape of patients with hepatocellular carcinoma.

Real-World Study Confirms Safety of Regorafenib After Sorafenib in Unresectable HCC

September 14, 2020

Regorafenib demonstrated a tolerable safety profile as treatment of patients with unresectable hepatocellular carcinoma in the real world, according to results from the ongoing prospective observational REFINE study.

Sequencing Challenges Impact the Management of Advanced Hepatocellular Carcinoma

August 26, 2020

In an interview with Targeted Oncology, Mehmet Akce, MD, discussed the treatment options available for patients with advanced hepatocellular carcinoma and how he would go about sequencing these treatments in his practice.

Addressing How to Treat Patients With Advanced Hepatocellular Carcinoma

August 07, 2020

Mehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.

OPTIMA Trial Will Continue to Follow Patients With HCC Treated With ThermoDox Combo

August 05, 2020

Patients with hepatocellular carcinoma, or primary liver cancer, treated with ThermoDox plus radiofrequency ablation in the phase 3 OPTIMA clinical trial will continue to be followed for overall survival.

New Study Supports Expanded Indication for Lenvatinib in Advanced HCC

July 18, 2020

Lenvatinib may benefit patients with advanced hepatocellular carcinoma with second- or later-line therapies and a high burden of intrahepatic lesions.

Data Monitoring Committee Recommends Stopping Phase 3 OPTIMA Trial in Hepatocellular Carcinoma

July 14, 2020

The independent Data Monitoring Committee recommended stopping the global phase 3 OPTIMA clinical trial evaluating the combination of ThermoDox with radiofrequency ablation in hepatocellular carcinoma or primary liver cancer.

HEPANOVA Trial Update: Final Patient With HCC Enrolled to Receive TTFields/Sorafenib

July 09, 2020

The last patient with advanced hepatocellular carcinoma was enrolled on the phase 2 HEPANOVA trial, which is investigating the combination of Tumor Treating Fields and sorafenib. The combination showed safety and tolerability for patients in an interim analysis.